NetraMark Holdings Inc.

AIAI

CA64119M1059

Software

Market Closed - Canadian Securities Exchange Other stock markets 02:52:39 2024-04-26 pm EDT			5-day change	1st Jan Change
0.315 ^CAD	0.00%		+1.61%	-10.00%

Apr. 10	Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	CI
Apr. 04	NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	CI

NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023

February 26, 2024 at 06:58 pm EST

NetraMark Holdings Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was CAD 0.0003 million compared to CAD 0.000778 million a year ago. Revenue was CAD 0.0003 million compared to CAD 0.000778 million a year ago.

Net loss was CAD 0.852526 million compared to CAD 2.08 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.05 a year ago.

Latest news about NetraMark Holdings Inc.

Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	Apr. 10	CI
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	Apr. 04	CI
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	Mar. 12	CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	Mar. 11	MT
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	Mar. 11	CI
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	Feb. 27	CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 26	CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	Feb. 26	CI
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	Feb. 15	CI
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering	Feb. 12	CI
NetraMark Up 8.6% After Reporting Third Contract With Biopharmaceutical Firm	Jan. 30	MT
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company	Jan. 30	CI
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 26	CI
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates	Jan. 16	CI
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights	Dec. 20	CI
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023.	Dec. 08	CI
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023.	Dec. 08	CI
NetraMark Holdings Inc. Announces Management Changes	Nov. 06	CI
NetraMark Holdings Inc. Signs Master Service Agreement with Large Biopharmaceutical Company	23-10-31	CI
NetraMark Holdings Inc. announced that it has received CAD 2 million in funding	23-09-18	CI
NetraMark Holdings Inc. announced that it expects to receive CAD 1.5 million in funding	23-09-10	CI
NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-17	CI
NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board	23-07-19	CI
National Bank on Canadian ETFs with AI Exposure	23-06-14	MT
NetraMark Holdings Inc. announced that it has received CAD 0.74235 million in funding	23-06-13	CI

Chart NetraMark Holdings Inc.

Duration

Period

More charts

Company Profile

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Companyâs product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.

Sector

Software

Calendar

2024-05-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Software

	1st Jan change	Capi.
NETRAMARK HOLDINGS INC.	-10.00%	15.45M
MICROSOFT CORPORATION	+8.05%	3,020B
SYNOPSYS INC.	+5.58%	82.93B
CADENCE DESIGN SYSTEMS, INC.	+3.69%	76.85B
DASSAULT SYSTÈMES SE	-14.62%	53.04B
PALANTIR TECHNOLOGIES INC.	+31.16%	50.15B
ATLASSIAN CORPORATION	-24.56%	46.71B
THE TRADE DESK, INC.	+17.75%	41.41B
SEA LIMITED	+55.21%	36.1B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-10.24%	24.64B